Wednesday, October 27, 2021
اُردُو نیوز Newspaper Live-TV(UK) Live-TV(PK)
اُردُو نیوز Newspaper
Live-TV(UK) Live-TV(PK)

Novartis launches Neupogen copycat Zarxio in US market

Novartis launches Neupogen copycat Zarxio in US market
September 3, 2015
ZURICH - Novartis AG has launched the first biosimilar drug in the United States after a US appeals court declined on Wednesday to stop the sale of the company's copycat version of Amgen Inc's blockbuster cancer drug Neupogen. Novartis unit Sandoz said on Thursday Zarxio (filgrastim-sndz) was now available in the United States. Zarxio is the first biosimilar approved by the US Food and Drug Administration and the first to launch in the US market, it added in a statement. -Reuters
تازہ ترین خبریں حاصل کرنے کے لیے فوری اطلاع کی اجازت دیں

آپ کسی بھی وقت دائیں طرف نیچے بیل آئیکن پر صرف ایک کلک کے ذریعے آسانی سے سبسکرائب کر سکتے ہیں۔